Celltrion Inc
KRX:068270

Watchlist Manager
Celltrion Inc Logo
Celltrion Inc
KRX:068270
Watchlist
Price: 193 900 KRW 0.73% Market Closed
Market Cap: 40.2T KRW
Have any thoughts about
Celltrion Inc?
Write Note

Celltrion Inc
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celltrion Inc
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Celltrion Inc
KRX:068270
Cash from Financing Activities
-â‚©196.8B
CAGR 3-Years
N/A
CAGR 5-Years
-3%
CAGR 10-Years
-20%
SK Bioscience Co Ltd
KRX:302440
Cash from Financing Activities
-â‚©89.6B
CAGR 3-Years
-288%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Cash from Financing Activities
â‚©82.8B
CAGR 3-Years
14%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
H
Hugel Inc
KOSDAQ:145020
Cash from Financing Activities
-â‚©181.7B
CAGR 3-Years
-91%
CAGR 5-Years
-19%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Financing Activities
-â‚©17.7B
CAGR 3-Years
-39%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Cash from Financing Activities
â‚©32.5B
CAGR 3-Years
-43%
CAGR 5-Years
33%
CAGR 10-Years
N/A
No Stocks Found

Celltrion Inc
Glance View

Market Cap
40.2T KRW
Industry
Biotechnology

Celltrion Inc. stands as a significant player in the global biopharmaceutical industry, rooted in the heart of South Korea's bustling innovation scene. Founded in 2002 by Seo Jung-Jin, the company initially carved its niche in the development of biosimilars, which are near-identical versions of original biological drugs whose patents have expired. With rapid advancements in biotechnology, Celltrion has well-positioned itself to tap into the expanding market for affordable and accessible biologic treatments. At the core of its operation is its cutting-edge production facilities equipped with high-tech fermentation and purification processes necessary for manufacturing these complex medicines. This foundational expertise has allowed Celltrion to pioneer some of the world's first monoclonal antibody biosimilars, including those for autoimmune diseases and oncological conditions, thereby cementing its reputation as a forerunner in global biosimilar development. The company’s revenue model is intricately tied to its production capabilities and strategic partnerships. By leveraging its advanced manufacturing infrastructure, Celltrion not only produces its own line of biosimilars but also collaborates with global pharmaceutical companies to license and distribute its products worldwide. Such partnerships have enabled Celltrion to penetrate markets across Europe, the Americas, and Asia, with its biosimilars gaining regulatory approval in many regions. Furthermore, Celltrion’s business is not limited to biosimilars; it is actively investing in novel biologics and innovative delivery systems. This diversification strategy underscores its commitment to sustainable growth and reducing dependence on any single product line, ultimately fostering a robust pipeline that promises to meet the healthcare industry's evolving demands.

Intrinsic Value
188 649.54 KRW
Overvaluation 3%
Intrinsic Value
Price

See Also

What is Celltrion Inc's Cash from Financing Activities?
Cash from Financing Activities
-196.8B KRW

Based on the financial report for Sep 30, 2024, Celltrion Inc's Cash from Financing Activities amounts to -196.8B KRW.

What is Celltrion Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-20%

Over the last year, the Cash from Financing Activities growth was 41%.

Back to Top